<DOC>
	<DOCNO>NCT01312636</DOCNO>
	<brief_summary>This study conduct Japan . The aim observational study evaluate long-term safety efficacy activate recombinant human factor VII ( NovoSeven® ) subject congenital FVII deficiency .</brief_summary>
	<brief_title>Observational Study Safety Efficacy NovoSeven® Subjects With Congenital FVII Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Congenital FVII deficiency Never treat NovoSeven® Patients already treatment NovoSeven® History hypersensitivity component NovoSeven®</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>